Results 31 to 40 of about 138,640 (301)

New developments in immunotherapy for lymphoma

Cancer Biology & Medicine, 2018
The development of immunotherapies for lymphoma has undergone a revolutionary evolution over the past decades. Since the advent of rituximab as the first successful immunotherapy for B-cell non-Hodgkin lymphoma over two decades ago, a plethora of new ...
Benjamin Heyman, Yiping Yang
doaj   +1 more source

Intracranial fusarium fungal abscess in an immunocompetent patient: case report and review of the literature. [PDF]

, 2014
Introduction Fusarium spp is an omnipresent fungal species that may lead to fatal infections in immunocompromised populations. Spontaneous intracranial infection by Fusarium spp in immunocompetent individuals is exceedingly rare.
Cadden, Joseph, Commins, Deborah, Giannotta, Steven L, Lee, Brian, Peterson, Asa, Pham, Martin H, Zada, Gabriel   +6 more
core   +1 more source

Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis

Frontiers in Immunology, 2023
BackgroundWe conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML).MethodsWe performed a literature search on PubMed ...
Moazzam Shahzad, Moazzam Shahzad, Andrea Nguyen, Ali Hussain, Mohammad Ammad-Ud-Din, Muhammad Salman Faisal, Ezza Tariq, Fatima Ali, Atif Butt, Iqra Anwar, Sibgha Gull Chaudhary, Forat Lutfi, Nausheen Ahmed, Anurag K. Singh, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq   +16 more
doaj   +1 more source

Chromosomal in situ suppression hybridization of immunologically classified mitotic cells in hematologic malignancies [PDF]

, 1992
Chromosomal in situ suppression (CISS) hybridization was performed with library DNA from sorted human chromosomes 8, 9, 15, 17, 21, and 22 on immunologically stained bone marrow cells of four patients with a hematologic neoplasm, including two patients ...
Arnoldus, Cremer, Cremer, Dauwerse, Edwards, Erber, Hopman, Johnson, Jotterand Bellomo, Knuutila, Knuutila, Larramendy, Larramendy, Lichter, Lichter, Marianne Tiainen, Martine Jotterand Bellomo, Patricia Emmerich, Perez Losada, Pinkel, Pinkel, Popp, Sakari Knuutila, Susanne Popp, Tapani Ruutu, Teerenhovi, Thomas Cremer, Valerie Parlier, Wessman, Willard   +29 more
core   +1 more source

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W, Ding, L-W, Doan, NB, Dong, X-M, Garg, M, Gery, S, Hattori, N, Huang, RY-J, Koeffler, HP, Lin, D-C, Liu, L-Z, Meng, X, Said, JW, Sun, Q-Y, Tang, K, Xiao, J-F, Yang, H   +16 more
core   +2 more sources

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Blood Neoplasia
: Patients with nucleophosmin 1 (NPM1)–mutated acute myeloid leukemia (AML) without a FLT3-internal tandem duplication mutation are considered to have favorable-risk disease that may be cured with intensive chemotherapy (7+3; IC) alone.
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo, Amy E DeZern, Gabriel Ghiaur, Lukasz P Gondek, William Brian Dalton, Theodoros Karantanos, Tania Jain, Gabrielle T Prince, Richard J Jones, B. Douglas Smith, Alexander J Ambinder   +14 more
doaj   +1 more source

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. [PDF]

, 2014
BackgroundBevacizumab and temsirolimus are active agents in gynecologic tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors.
Falchook, Gerald S, Fu, Siqing, Hong, David S, Kurzrock, Razelle, Levenback, Charles, Lu, Karen, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J   +9 more
core   +3 more sources

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

Haematologica, 2014
Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal.
Joshua F. Zeidner, Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Jacqueline M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt   +11 more
doaj   +1 more source

Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor

Experimental Hematology & Oncology, 2022
Background Thioredoxin-1 (TXN1) is one of the major cellular antioxidants in mammals and is involved in a wide range of physiological cellular responses.
Shaima Jabbar, Parker Mathews, Xiaobei Wang, Pasupathi Sundaramoorthy, Emily Chu, Sadhna O. Piryani, Shengli Ding, Xiling Shen, Phuong L. Doan, Yubin Kang   +9 more
doaj   +1 more source

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]

, 2019
PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia, Bohlke, Kari, Castelli, Roberto, Djulbegovic, Benjamin, Lazo-Langner, Alejandro, Lustberg, Maryam B, Martino, Massimo, Mountzios, Giannis, Peswani, Namrata, Porter, Laura, Tanaka, Tiffany N., Trifirò, Gianluca, Yang, Hushan   +12 more
core   +3 more sources